SNPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Synopsys Inc. is not a strong buy for a beginner, long-term investor at this moment. While the company has shown significant revenue growth in Q1 2026, its declining net income, EPS, and gross margin, coupled with bearish technical indicators and recent analyst downgrades, suggest caution. Additionally, hedge funds are selling the stock, and the options data indicates bearish sentiment. While Congress trading data shows positive sentiment, it is not enough to offset the broader concerns. A hold position is recommended until clearer positive trends emerge.
The technical indicators are bearish. The MACD is above 0 but contracting, RSI is neutral at 41.913, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 417.651 and resistance at 433.626.
Congress members have made two recent purchase transactions, showing positive sentiment.
Revenue increased by 65.52% YoY in Q1
Analysts have highlighted potential sequential growth for the rest of the year.
Hedge funds are selling heavily, with a 427.09% increase in selling activity last quarter.
Analysts have downgraded the stock recently, citing decelerating growth in the electronic design automation business and muted IP revenue growth.
The company's Q1 net income dropped by 78.03% YoY, EPS fell by 82.01% YoY, and gross margin declined by 17.38% YoY.
Options data indicates bearish sentiment with a high put-call ratio.
In Q1 2026, Synopsys reported a 65.52% YoY revenue increase to $2.41 billion. However, net income dropped by 78.03% YoY to $64.96 million, EPS fell by 82.01% YoY to $0.34, and gross margin decreased by 17.38% YoY to 67.06%. The company issued conservative guidance for FY26, which has weighed on investor sentiment.
Recent analyst ratings are mixed to negative. Morgan Stanley downgraded the stock to Equal Weight with a reduced price target of $480, citing decelerating growth. Piper Sandler lowered its price target to $430, maintaining a Neutral rating. HSBC downgraded the stock to Hold with a $455 price target, citing uncertainties in its core business. However, some analysts, like JPMorgan, maintain an Overweight rating with a higher price target of $650, viewing the FY26 guidance as conservative.
